Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
Abroad (travel likely)RecruitingPHASE2
Conditions
Advanced Unresectable Hepatocellular Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Johns Hopkins, Baltimore, Maryland, United States
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
University of Texas Southwestern, Dallas, Texas, United States
START Dallas Fort Worth, Fort Worth, Texas, United States